Fidelity Investments’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Fidelity Investments’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,181	Closed	-$7.57K	–	5624
2023 Q2	$7.57K	Buy	4,181 +335	+9%	+$613	﹤0.01%	4239
2023 Q1	$5.08K	Buy	3,846 +289	+8%	+$473	﹤0.01%	4386
2022 Q4	$6.01K	Buy	3,557 +3,097	+673%	+$3.92K	﹤0.01%	4192
2022 Q3	$1K	Buy	460 +322	+233%	+$960	﹤0.01%	4776
2022 Q2	$0	Buy	+138	New	+$843	﹤0.01%	5649

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Fidelity Investments's PRDS Position: Q3 2023 in Review

Fidelity Investments sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 4,181 shares — an estimated $7.57K sold.

Fidelity Investments first reported a position in PRDS in Q2 2022 and held it in 5 quarters. The position peaked at $7.57K in Q2 2023. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Fidelity Investments reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Fidelity Investments sold 4,181 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $7.57K.
Fidelity Investments first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Fidelity Investments's Pardes Biosciences, Inc. Common Stock position peaked at $7.57K in Q2 2023.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.